Mark S Wolff

Prof. Dr. Mark S Wolff

School of Dental Medicine, University of Pennsylvania, Philadelphia, Mississippi, USA
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1994 in Archives of Oral Biology
Verified
Journal Article
Closed access
IKI. Kleinberg
I. Kleinberg
HKH.W. Kaufman
H.W. Kaufman
Mark S WolffMark S Wolff
Mark S Wolff

2 September 2021 in Dental Materials
Verified
Journal Article
Closed access
CRCamila S. Rodrigues
Camila S. Rodrigues
SDSukirti Dhital
Sukirti Dhital
JKJeongho Kim
Jeongho Kim
LMLiliana Gressler May
Liliana Gressler May
Mark S WolffMark S Wolff
Mark S Wolff
YZYu Zhang
Yu Zhang

28 February 2023 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
JPJoshua Petimar
Joshua Petimar
LGLaura Gibson
Laura Gibson
Mark S WolffMark S Wolff
Mark S Wolff
NMNandita Mitra
Nandita Mitra
PCPatricia Corby
Patricia Corby
CRChristina A. Roberto
Christina A. Roberto

1 April 2011 in Journal of Dental Education
Verified
Journal Article
Closed access
PDF file
DSDonna Shelley
Donna Shelley
JAJaime Anno
Jaime Anno
TTTuo-Yen Tseng
Tuo-Yen Tseng
GCGreg Calip
Greg Calip
JWJohn Wedeles
John Wedeles
Mark S WolffMark S Wolff
Mark S Wolff

23 October 2021 in Journal of Dental Research
Verified
Journal Article
Closed access
PDF file
EHE.V. Hersh
E.V. Hersh
Mark S WolffMark S Wolff
Mark S Wolff
PMP.A. Moore
P.A. Moore
KTK.N. Theken
K.N. Theken
HDH. Daniell
H. Daniell
The emergence of the COVID-19 viral pandemic has generated a renewed interest in pharmacologic agents that target the renin angiotensin system (RAS). Angiotensin-converting enzyme 1 (ACE1) inhibitors decrease the synthesis of angiotensin II (Ang II) from its precursor angiotensin I and inhibit the breakdown of bradykinin, while Ang II receptor blockers antagonize the action of Ang II at the receptor level downstream. The actions of both classes of drugs lead to vasodilation, a blunting of sympathetic drive and a reduction in aldosterone release, all beneficial effects in hypertension and congestive heart failure. ACE2 cleaves the vasoconstrictor Ang II to produce the anti-inflammatory cytoprotective angiotensin 1–7 (Ang 1–7) peptide, which functions through the G protein–coupled receptor MAS to counteract the pathophysiologic effects induced by Ang II via its receptors, including vasoconstriction, inflammation, hypercoagulation, and fibrosis. SARS-CoV-2 enters human cells by binding ACE2 on the cell surface, decreases ACE2 activity, competes for ACE2 receptor-binding sites, and shifts the RAS toward an overexpression of Ang II, accounting for many of the deleterious effects of the virus. Thus, there is great interest in developing recombinant ACE2 as a therapeutic for prevention or treatment of COVID-19. Notably, ACE2 is highly expressed in the oral cavity, and saliva and dorsum of the tongue are major reservoirs of SARS-CoV-2. Cost-effective methods to debulk the virus in the oral cavity may aid in the prevention of viral spread. Here we review the pharmacology of targeted small molecule inhibitors of the RAS and discuss novel approaches to employing ACE2 as a therapeutic for COVID-19.

29 May 2023 in Journal of Dental Research
Verified
Journal Article
Open access
HGH. Guan
H. Guan
MNM. Nuth
M. Nuth
SWS.R. Weiss
S.R. Weiss
AFA. Fausto
A. Fausto
YLY. Liu
Y. Liu
RRRobert Ricciardi
Robert Ricciardi
The COVID-19 pandemic has escalated the risk of SARS-CoV-2 transmission in the dental practice, especially as droplet-aerosol particles are generated by high-speed instruments. This has heightened awareness of other orally transmitted viruses, including influenza and herpes simplex virus 1 (HSV1), which are capable of threatening life and impairing health. While current disinfection procedures commonly use surface wipe-downs to reduce viral transmission, they are not fully effective. Consequently, this provides the opportunity for a spectrum of emitted viruses to reside airborne for hours and upon surfaces for days. The objective of this study was to develop an experimental platform to identify a safe and effective virucide with the ability to rapidly destroy oral viruses transported within droplets and aerosols. Our test method employed mixing viruses and virucides in a fine-mist bottle atomizer to mimic the generation of oral droplet-aerosols. The results revealed that human betacoronavirus OC43 (related to SARS-CoV-2), human influenza virus (H1N1), and HSV1 from atomizer-produced droplet-aerosols were each fully destroyed by only 100 ppm of hypochlorous acid (HOCl) within 30 s, which was the shortest time point of exposure to the virucide. Importantly, 100 ppm HOCl introduced into the oral cavity is known to be safe for humans. In conclusion, this frontline approach establishes the potential of using 100 ppm HOCl in waterlines to continuously irrigate the oral cavity during dental procedures to expeditiously destroy harmful viruses transmitted within aerosols and droplets to protect practitioners, staff, and other patients.